GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Changzhou Qianhong Biopharma Co Ltd (SZSE:002550) » Definitions » Valuation Rank

Changzhou Qianhong Biopharma Co (SZSE:002550) Valuation Rank


View and export this data going back to 2011. Start your Free Trial

What is Changzhou Qianhong Biopharma Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Changzhou Qianhong Biopharma Co Valuation Rank Related Terms

Thank you for viewing the detailed overview of Changzhou Qianhong Biopharma Co's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Changzhou Qianhong Biopharma Co (SZSE:002550) Business Description

Traded in Other Exchanges
N/A
Address
Number 90 Changjiang Middle Road, Xinbei distract, Jiangsu Province, Changzhou, CHN, 213022
Changzhou Qianhong Biopharma Co Ltd engages in the research and development, production, and sale of biopharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; and kallidinogenase kallikrein and heparinoid.
Executives
Wang Ke Directors, executives
Jiang Wen Qun Supervisors
Zou Shao Bo Executives
Wei Li Jun Executives
Mei Chun Wei Executives
Zhou Xiang Directors, executives
Zhao Gang Director
Ye Hong Ping Executives
Liu Jun Director
Fan Yong Executives
Jiang Jian Ping Supervisors
Wang Yao Fang Director
Hai Tao Directors, executives
Wang Yi Director